Review Article

The Role of PPARγ Receptors and Leukotriene B4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer

Thomas E. Adrian,1,2 Rene Hennig,2,3 Helmut Friess,3 and Xianzhong Ding2

1 Department of Physiology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
2 Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611-3008, USA
3 Department of Surgery, Technische Universitaet Muenchen, 81675 Munich, Germany

Correspondence should be addressed to Thomas E. Adrian, tadrian@uaeu.ac.ae

Received 12 June 2008; Accepted 22 October 2008

Recommended by Dipak Panigrahy

Pancreatic cancer is a devastating disease in which current therapies are inadequate. Separate lines of research have identified the 5-lipoxygenase/leukotriene B4 receptor pathway and the PPARγ pathway as potential targets for prevention or treatment of this disease. LY293111 was originally designed as a potent leukotriene B4 receptor antagonist for treatment of inflammatory conditions. LY293111 was also known to have inhibitory effects on 5-lipoxygenase, which is upstream of the production of leukotrienes. LY293111 was shown to have potent anticancer effects in pancreatic cancer and several other solid malignancies, where it caused cell cycle arrest and marked apoptosis. Subsequently, it came to light that LY293111 exhibited PPARγ agonist activity in addition to its effects on the 5-lipoxygenase pathway. This raises the question of which of the two targets is of greatest importance with regard to the anticancer effects of this agent. The evidence to date is not conclusive, but suggests that the effects of LY293111 may be mediated by both LTB4 receptors and PPARγ.

Copyright © 2008 Thomas E. Adrian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Pancreatic Cancer is a devastating disease with more than 80% of all patients presenting with surgically inoperable tumors. It remains the fourth leading cause of cancer death in both men and women in the USA. The median survival is usually less than six months even with the addition of chemotherapy [1–3]. Surgical resection is the only effective treatment option, but there are few long-term survivors even after apparent curative resection [1–3]. Alternative effective treatment strategies are desperately needed for this disease.

1.1. Fatty acids and human cancer

Epidemiological and animal studies show that a high fat consumption is associated with a higher incidence and growth of tumors at several specific organ sites including breast, pancreas, and prostate [4–11]. Recent studies indicate that diets containing a high proportion of polyunsaturated omega-6 fatty acids (n-6 FA), such as linoleic acid (the precursor of arachidonic acid) are associated with a more advanced disease stage at the time of diagnosis of several kinds of cancer [4–6, 8, 10, 11]. In contrast, long-chain n-3 fatty acids, such as docosahexaenoic acid and eicosapentaenoic acid (EPA) inhibit the growth and metastasis of several cancers including pancreatic cancer [7, 9]. Omega 3 fatty acids inhibit tumor growth by a number of mechanisms including suppression of COX-2 expression and, for EPA at least, the alternative substrate produces different cyclooxygenase (PGE3) and lipoxygenase (LTB5) products that have anti-inflammatory and anticancer effects.

1.2. Eicosanoid pathways

Arachidonic acid is a substrate for three distinctively different enzymatic pathways. Among them, prostaglandin endoperoxide synthases (cyclooxygenases) catalyze the committed step that leads to prostaglandin biosynthesis [12–14]. The second pathway is the epoxygenase pathway that appears to have no role in cancer. The third pathway for metabolizing arachidonic acid, the lipoxygenase pathway catalyzes
the incorporation of one oxygen molecule into polyunsaturated fatty acids to yield a 1-hydroperoxy-2, 4-trans, cis-pentadiene product [14–16]. Mammalian lipoxygenases possess regiospecificity during interaction with substrate, and on this basis have been designated as arachidonate 5-, 12-, and 15-lipoxygenase (5-LOX, 12-LOX, and 15-LOX) [14–16]. The three distinct enzymes insert oxygen at carbon 5, 12, or 15 of arachidonic acid, and the primary product is 5S-, 12S-, or 15S-hydroperoxyeicosatetraenoic acid (5-, 12-, or 15-HPETE), which can be further reduced by glutathione peroxidase to hydroxy forms (5-, 12-, 15-HETE), respectively [14–16]. 5-LOX is noteworthy because it is the only pathway that can turn arachidonic acid into leukotrienes [15, 17]. The activity of 5-LOX is dependent upon a second factor termed 5-LOX-activating protein (FLAP) [15, 17]. Considerable effort has been expended by the pharmaceutical industry to produce inhibitors of FLAP, 5-LOX as well as leukotriene antagonists, because the 5-LOX products, leukotrienes (LTB₄, LTC₄, LTD₄, and LTE₄) have been implicated as mediators of inflammation and immediate hypersensitivity reactions, in particular, human bronchial asthma [18, 19].

1.3. Leukotriene receptor antagonists and the development of LY293111

The pharmaceutical industry has focused on several targets to suppress leukotriene activity in inflammatory conditions such as bronchial asthma [18, 19]. One approach is to directly inhibit 5-lipoxygenase activity, thereby blocking secretion of all leukotrienes. The most widely studied clinical inhibitor of 5-lipoxygenase is zileuton, which inhibits the active site of 5-lipoxygenase at concentrations that do not inhibit cyclooxygenase, 12-lipoxygenase, or 15-lipoxygenase [18–22]. Another avenue to inhibit leukotriene formation is via blocking FLAP activity, thus preventing cytoplasmic to membrane translocation and activation of 5-lipoxygenase [16–18]. MK-0591 is a widely used 5-lipoxygenase-activating protein inhibitor for biomedical research [16–18]. Even though it strongly inhibits 5-lipoxygenase activity and blocks leukotriene generation, its use in clinic is limited by marked side effects. The final pharmacological approach to block leukotriene activity is to selectively block the actions of LTB₄ or the sulfidopeptide leukotrienes using specific receptor antagonists.

Several synthetic LTB₄ receptor antagonists have been developed. Early compounds included SC-41930; ONO-4057, which was orally active; LY223982, a benzophenone dicarboxylic acid; and LY255283 a hydroxyacetophenone [23–27]. These latter two compounds from the Lilly Research Laboratories potently block LTB₄ binding to its receptors within the nM range and inhibit the biological functions of LTB₄ in vitro [28, 29]. Unfortunately, they showed poor oral bioavailability [28]. In 1995, investigators at the Lilly Research Laboratories reported a new LTB₄ antagonist, LY293111. This compound is a novel derivative of LY255283, but is orally stable and more potent as an LTB₄ receptor antagonist [28, 29]. Compared with other LTB₄ receptor antagonists, LY293111 is superior at blocking the cellular functions induced by LTB₄ [28, 30].
1.4. Inflammation, Cyclooxygenases, Lipoxigenases, and Cancer

The epidemiological data show a clear and strong association between chronic inflammatory conditions and cancer development, even though the conditions causing inflammation may vary [31–36]. It can be due to chronic infection caused by a virus, bacteria, or parasite or it may be due to noninfectious, physical, or chemical irritant [31–36]. For example, chronic infection with the bacterium Helicobacter pylori causes atrophic gastritis, which can lead to dysplasia and adenocarcinoma [37]. Hepatitis B and C viruses account for more than 80% of cases of hepatocellular carcinoma worldwide [34]. The inflammatory bowel diseases, ulcerative colitis and Crohn’s disease, predispose to the development of cancers of the large bowel and/or terminal ileum, although a causative infectious agent has never been conclusively identified [38]. For noninfectious inflammation, chronic reflux of gastric acid and bile into the distal esophagus causes chemical injury and on the long-term can lead to Barrett’s esophagus and eventually to esophageal adenocarcinoma [35]. Thus it is apparent that chronic inflammation is a common underlying theme in the development of many different malignancies.

Although the mechanisms for the association between inflammation and cancer are not fully understood, growth factors, cytokines, and chemokines released into inflammatory environment are associated with tumor development and progression [32, 36]. High concentrations of free radicals and nitric oxide can induce DNA damage and promote cancer development [32, 36]. Over the past decade, much attention has been paid on the role of cyclooxygenases in cancer development, specifically its inducible isofrom, the cyclooxygenase 2 (COX-2) [39–41]. COX-2 is active within both inflamed and malignant tissues [37–39]. The expression of COX-2 and COX-2 metabolites increases during the multistage progression of tumors [39–41]. By metabolizing arachidonic acid to prostaglandins, COX-2 induces cellular resistance to apoptosis, modulation of cellular adhesion and motility, promotion of angiogenesis, and immunosuppression [42–47]. Epidemiological data has implicated COX-2 in the pathogenesis of a number of epithelial malignancies, especially colorectal cancer [48, 49]. Inhibition of the enzyme with COX inhibitors is associated with a dramatic reduction in the incidence, morbidity and mortality of colorectal cancer [48–51]. Recent attention has also been focused on the role of 5-LOX, 12-LOX, and 15-LOX in cancer [52–60]. In pancreatic cancer, activation of the 5-LOX and 12-LOX pathways enhances cancer cell proliferation, while the 15-LOX pathway is protective against cancer development [61–64].

1.5. The 5-lipoxygenase/leukotriene B4 pathway and cancer

Accumulating evidence suggests that the 5-LOX pathway has profound influence on the development and progression of human cancers [61–64]. 5-LOX is overexpressed in pancreatic cancer tissues but is not expressed in normal pancreatic ductal cells [65]. Furthermore, this pathway is already up-regulated in pancreatic intraepithelial neoplasias (PanINs), which are the precursor lesions of pancreatic adenocarcinoma [66]. Blockade of 5-LOX activity inhibits proliferation and induces apoptosis in pancreatic cancer cells both in vitro and in vivo [67–69]. Pancreatic cancer cells secrete LTB4 and LTB4 induces proliferation in these cells [62]. Two G-protein-coupled LTB4 receptors (BLT1 and BLT2) have been cloned and characterized. BLT1 and BLT2 are high- and low-affinity LTB4 receptors, respectively, and form a gene cluster in humans. Both BLT1 and BLT2 are up-regulated in pancreatic cancer tissues, and expression was
Thymidine incorporation, it was not able to block the inhibitory receptors. While GW9662 alone was able to significantly increase

Figure 4 PPAR Research

As with other proteins in the 5-LOX/LTB4 pathway, BLT1 and PPARγ1.6. PPARγ may be valuable targets for chemoprevention.

pancreatic adenocarcinomas [70]. This suggests that they BLT2 are already up-regulated in pancreatic intraepithelial

express both the PPARγ receptor and LTB4 (BLT1 and BLT2) receptors. While GW9662 alone was able to significantly increase thymidine incorporation, it was not able to block the inhibitory effect of different concentrations of LY293111.

seen in all of the tested pancreatic cancer cell lines [65, 70]. As with other proteins in the 5-LOX/LTB4 pathway, BLT1 and BLT2 are already up-regulated in pancreatic intraepithelial neoplasias (PanIN lesions) which are the precursors of pancreatic adenocarcinomas [70]. This suggests that they may be valuable targets for chemoprevention.

1.6. PPARγ and pancreatic cancer

Peroxisome proliferator activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPARγ is expressed at high levels in adipose tissue and plays a central role in adipocyte differentiation and energy homeostasis. Recent studies have implicated PPARγ in the pathogenesis of several human malignancies [71–74]. Previous studies have suggested that PPARγ is up-regulated in pancreatic cancer [75]. Our own studies, employing two separate commercially available antibodies, show that PPARγ is expressed in pancreatic cancer, but that expression in the cancer cells does not appear to be different from that in normal pancreatic ductal cells (Figure 1). In contrast, PPARγ staining was seen in the islets surrounding cancers, but not in islet cells from normal pancreatic tissues obtained from multiorgan donors (Figure 1). In animal models, PPARγ ligands have preventive effects against chemical carcinogenesis [76]. Several studies have shown that PPARγ agonists, including the natural ligand 15-deoxy-Δ12,14-prostaglandin J2, and thiazolidinedione antidiabetic agents, such as ciglitizone and rosiglitizone, inhibit growth and induce apoptosis in pancreatic cancer [75, 77–81]. In contrast, one paper suggests induction of differentiation without apoptosis [82]. The apoptosis appears to be preceded by a morphological change to a more differentiated cell type which perhaps undergoes apoptosis when DNA repair turns out to be not possible [80]. In some studies, PPARγ agonists also block invasion and angiogenesis [83, 84]. However, this is controversial since PPARγ agonists induce secretion of vascular endothelial growth factor, which would have a promoting effect on metastatic tumor growth [85].

1.7. LY293111 and cancer

As might be expected from the growth-stimulatory effects of LTB4 in pancreatic cancer, the LTB4 receptor antagonist, LY293111 inhibits cancer growth and induces apoptosis both in vitro and in vivo [86–89]. LY293111 inhibits proliferation and induces apoptosis in a wide range of pancreatic cancer cell lines as well as cells of other tumor types, such as breast, prostate, and colon cancer cells [86–89]. These effects on growth and apoptosis are both time and concentration dependent, with effects seen at 100–500 nM in vitro [86, 87]. To confirm the involvement of LTB4 receptors in mediating the effect of LY293111 on human pancreatic cancer cell proliferation, another selective LTB4 receptor antagonist, U75302 was used in comparison with a selective LTD4 antagonist, LY171883 [86]. U75302 inhibits the proliferation of pancreatic cancer cells; but it is less potent than LY293111 as expected from the lower receptor affinity of this drug [28, 29, 90]. In contrast, the selective LTD4 antagonist, LY171883 had no significant effect on pancreatic cancer cell growth. LY293111 causes cell cycle arrest in the S phase of the cell cycle with suppression of expression of cyclin A, cyclin E, and cdk2. In parallel with growth inhibition, LY293111 induced apoptosis in all cancer cell lines tested [86, 87]. LY293111 induced dramatic morphological changes in human pancreatic cancer cells following a short period of treatment [86, 87]. The treated cells became rounded and exhibited membrane blebbing, chromatin condensation, and nuclear fragmentation, finally they were detached from the microplate. Induction of DNA fragmentation by LY293111 was confirmed by TUNEL assay (terminal deoxynucleotidyl transferase-mediated nick end labeling) and apoptosis was also established by annexin V binding [86, 87]. Apoptosis is triggered through the mitochondrial pathway, with a change in the ratio of proapoptotic proteins, such as Bax to antiapoptotic proteins, such as Bcl-2 and Mcl-1, release of cytochrome C, activation of caspase (but not caspase 8), and subsequent activation of the downstream caspase cascade with activation of caspase 3 and caspase 7 and cleavage of the caspase 3 substrate, poly ADP-ribose polymerase (PARP) [87].

LY293111 markedly slows down the growth of subcutaneous xenografts of human pancreatic cancer in athymic mice at a dose of 250 mg/kg/day [86]. To confirm the antipancreatic cancer effect of LY293111, pancreatic cancer cells with stable expression of enhanced green fluorescent protein (GFP) were orthotopically implanted into the duo-
denal lobe of the pancreas of athymic mice. Our data show that LY293111 significantly inhibits the growth of the orthotopically implanted pancreatic cancer cells in concert with blocking metastatic spread to the liver and other organs.
LY293111 also dramatically increased the number of TUNEL positive cells in pancreatic tumors harvested from the subcutaneous transplant experiments in athymic mice [86, 91].

1.8. LY293111 as a PPARγ agonist

Following the disclosure of anticancer effects of LY293111, researchers at the Lilly Research Laboratories found that LY293111 is also a PPARγ agonist [92, 93]. This finding was initially based on structural analysis and was supported by functional studies. The PPARγ agonist activity of LY293111 is evidenced by its ability to induce adipogenic differentiation in vitro [92]. Normalization of circulating glucose levels by LY293111 in the ZDF rat diabetes model further suggests that LY293111 is an antidiabetic, PPARγ agonist [92]. Further studies suggested that the anticancer effect of LY293111 might be mediated, at least in part, by PPARγ [92, 93]. More extensive studies have subsequently shown that LY293111 is also an inhibitor of 5-lipoxygenase, although this effect is less potent than the LTB4 and PPARγ targets.

1.9. Mechanisms by which LY293111 functions in cancer

Since our findings suggest that all pancreatic cancer cells express both PPARγ and BLT1, it is possible that the anticancer effects of LY293111 could be mediated by either receptor or both receptors. It has been reported that PPARγ negative-expressing cancer cells are less responsive to LY293111-induced growth inhibition [92, 93]. However, there is also evidence in favor of BLT1 being the major target. Firstly, the effects of LY293111 on proliferation and apoptosis are extremely potent. A comparison between the effects of LY293111 and the PPARγ agonist, ciglitazone is shown in Figure 2. As this figure shows, LY293111 is approximately 10 times more potent than ciglitazone in inhibiting the proliferation of Panc-1 and S2-O13 human pancreatic cancer cells. LY293111 was also more potent than another PPARγ agonist, rosiglitazone and the PPARα agonist, WY-14643. The antiproliferative effects and induction of apoptosis are seen at 250 nM LY293111, which is much lower than the IC50 of the drug for PPARγ receptors (~ 4 μM) [92, 93]. Indeed, its effects on cancer cells are more potent than several PPARγ agonists, including ciglitazone and rosiglitazone. Secondly, LY293111 is able to completely inhibit the effects of LTB4 on proliferation and MAP kinase activation in pancreatic cancer cells [62]. However, preliminary studies have shown that the antiproliferative effects of LY293111 in pancreatic cancer are not inhibited by the PPARγ antagonist, GW9662 in vitro (Figure 3). Finally, data from our own studies and those of others show that PPARγ agonists induce cell cycle arrest in the G0/G1 phase, whereas LY293111 induces S phase cell cycle arrest [82, 87]. It is even possible that anticancer effects of LY293111 might also be partially mediated by other unknown mechanisms. However, based on the current data, both the leukotriene B4 receptor and PPARγ are likely to be involved in the antitumor activity of LY293111.

2. EFFECT OF LY293111 IN COMBINATION WITH OTHER AGENTS IN CANCER

Several studies have demonstrated that LY293111 enhances anticancer effects of gemcitabine, which is widely used as the standard therapy in pancreatic cancer patients in adjuvant and palliative treatment settings [89, 91, 94]. Gemcitabine only improves survival by a few weeks, but clinical data show improvement in the quality of life for pancreatic cancer patients. The effects of LY293111 in combination with gemcitabine were investigated in an orthotopic model of pancreatic cancer in athymic mice [91]. This model is superior to subcutaneous transplantation since it is less likely to modify the biological characteristic of pancreatic cancer cells, providing a favourable growth environment for them. It also allows easy monitoring of hepatic and lymph node metastasis with GFP stable expressing cells. In this model, animals without any treatment following implantation of GFP-expressing, S2-O13 pancreatic cancer cells developed end-stage disease with invasive cancer obstructing the duodenum and bile duct [91]. The animals develop liver, lung, and lymph node metastases and eventually peritoneal carcinomatosis with malignant ascites and cachexia [91]. Either gemcitabine or LY293111 alone significantly inhibited tumor growth and reduced the incidence of liver metastasis. However the combination of LY293111 and gemcitabine was significantly more effective than either treatment alone in blocking tumor growth [91]. Combined treatment also significantly relieved tumor-induced cachexia and maintained stable body weights compared with either drug alone, and also significantly decreased the incidence of biliary obstruction and metastasis [91]. These experimental results show that combined therapy of gemcitabine and LY293111 potently inhibits the growth and metastases of the very rapidly growing and aggressive pancreatic adenocarcinoma and suggest that it might be a valuable way for treatment of pancreatic cancer patients. LY293111 has also been shown to increase the effectiveness of gemcitabine in a colon cancer model [89]. The in vitro effects of LY293111 have been tested with other classical chemotherapeutic agents. The effects of the active metabolite of irinotecan, SN-38 or the active metabolite of capecitabine, 5′-DFUR were enhanced by LY293111 in multiple cell lines, including breast, bladder, and sarcoma cells [94].

3. CLINICAL TRIALS WITH LY293111

Three phase I clinical trials with LY293111 alone or in combination with gemcitabine or irinotecan have been reported. LY293111 was generally well tolerated [95–97]. The side effects were mild to moderate; the major ones gastrointestinal with diarrhea and pain. These initial phase I trials looked promising and LY293111 could be safely administered orally [95–97]. For example, in combination with gemcitabine, three patients had partial responses [96]. One had pancreatic cancer previously treated with gemcitabine, one with pancreatic cancer previously treated with 5-flouracil and radiation, and one with non-small-cell lung cancer treated with one prior regimen. Two phase II
trials have been completed and preliminary data reported in abstract form [98, 99]. One of these compared the combination of LY293111 with gemcitabine compared with gemcitabine with placebo in pancreatic cancer [98]. The second compared LY293111 with cisplatin and gemcitabine versus the placebo combined with the latter two drugs in patients with non-small-cell lung cancer [99]. Unfortunately, LY293111 did not improve progression-free survival in either of these two trials [98, 99].

4. CONCLUSIONS

LY293111 is an interesting compound that has biological effects on several different targets. It acts as an antagonist on LTB4 receptors, as a PPARy agonist and as a 5-lipoxygenase inhibitor. Indeed, some investigators have referred to LY293111 as a multiple eicosanoid pathway inhibitor [94, 99]. Since LY293111 has anticancer effects on multiple tumor types, the target involved in mediating the effects of the drug is clearly of interest. The evidence to date is not conclusive, but suggests that effects may be mediated by both LTB4 receptors and PPARs. Preliminary reports regarding the phase II clinical trials have unfortunately been disappointing. It remains unknown whether this compound will eventually find a use in the clinic for cancer therapy; however, this recent clinical experience perhaps makes this unlikely now.

REFERENCES

[1] M. Jafari and J. L. Abbruzzese, “Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup pancreatic cancer task force,” Surgical Oncology Clinics of North America, vol. 13, no. 4, pp. 751–760, 2004.
[2] N. Alexakis, C. Halloran, M. Raraty, E. Li-Stiles, et al., “Arachidonic acid metabolism in the skin,” Journal of Nutritional Science and Vitaminology, vol. 47, no. 4, pp. 261–268, 2001.
[3] D. Goldstein, S. Carroll, M. Apte, and G. Keogh, “Modern management of pancreatic carcinoma,” Internal Medicine Journal, vol. 34, no. 8, pp. 475–481, 2004.
[4] M. P. Fay, L. S. Freedman, C. K. Clifford, and D. N. Midthune, “Effect of dietary types and amounts of fat on the development of mammary tumors in rodents: a review,” Cancer Research, vol. 57, no. 18, pp. 3979–3988, 1997.
[5] P. Clerc, N. Bensaadi, P. Pradel, A. Estival, F. Clemente, and N. Vaysse, “Lipid-dependent proliferation of pancreatic cancer cell lines,” Cancer Research, vol. 51, no. 14, pp. 3633–3638, 1991.
[6] T. L. Dao and R. Hilf, “Dietary fat and breast cancer: a search for mechanisms,” Advances in Experimental Medicine and Biology, vol. 322, pp. 223–237, 1992.
[7] R. Karmali, “n-3 fatty acids: biochemical actions in cancer,” Journal of Nutritional Science and Vitaminology, pp. 148–152, 1992.
[8] D. P. Rose and J. M. Connolly, “Dietary fat and breast cancer metastasis by human tumor xenografts,” Breast Cancer Research and Treatment, vol. 46, no. 2-3, pp. 225–237, 1997.
[9] D. P. Rose, “Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies,” American Journal of Clinical Nutrition, vol. 66, supplement 6, pp. 1513S–1522S, 1997.
[10] S. M. Fischer, R. A. Hagerman, E. Li-Stiles, et al., “Arachidonate has protumor-promoting action that is inhibited by linoleate in mouse skin carcinogenesis,” Journal of Nutrition, vol. 126, supplement 4, pp. 1095S–1104S, 1996.
[11] V. A. Ziboh, “Arachidonic acid metabolism in the skin,” in Arachidonic Acid Metabolism and Tumor Promotion, S. M. Fischer and T. J. Slaga, Eds., pp. 5–20, Martinus Nijhoff, Boston, Mass, USA, 1985.
[12] M. S. Simonson, J. A. Wolfe, and M. J. Dunn, “Regulation of prostaglandin synthesis by differential expression of the gene encoding prostaglandin endoperoxide synthase,” in Advances in Prostaglandin, Thromboxane and Leukotriene Research, B. Sammuelsson, P. Ramwell, and R. Paolotti, Eds., pp. 21–69, Raven Press, New York, NY, USA, 1990.
[13] W. L. Smith, D. L. DeWitt, S. A. Kraemer, et al., “Structure function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases,” in Advances in Prostaglandin, Thromboxane and Leukotriene Research, B. Samuelssson, Ed., Raven Press, New York, NY, USA, 1990.
[14] M. J. Holtzman, V. Zhang, H. Hussain, W. T. Roswit, and J. D. Wilson, “Prostaglandin H synthase and lipoxigenase gene families in the epithelial cell barrier;” Annals of the New York Academy of Sciences, vol. 744, pp. 58–77, 1994.
[15] C. D. Funk, “The molecular biology of mammalian lipoxigenases and the quest for eicosanoid functions using lipoxigenase-deficient mice,” Biochimica et Biophysica Acta, vol. 1304, no. 1, pp. 65–84, 1996.
[16] C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001.
[17] M. Peters-Golden and T. G. Brock, “5-lipoxygenase and FLAP,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 69, no. 2-3, pp. 99–109, 2003.
[18] C. A. Sorkness, “The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma,” Pharmacotherapy, vol. 17, no. 1, part 2, pp. 50S–54S, 1997.
[19] J. M. Negro, J. C. Miralles, J. L. Ortiz, E. Funes, and A. Garcia, “Biosynthesis inhibitors for leukotrienes in bronchial asthma,” Allergologia et Immunopathologia, vol. 25, no. 4, pp. 209–216, 1997.
[20] A. R. Leff, “Discovery of leukotrienes and development of antileukotriene agents,” in Annals of Allergy, Asthma and Immunology, vol. 86, no. 6, supplement 1, pp. 4–8, 2001.
[21] S. W. Djuric, P. W. Collins, P. H. Jones, et al., “7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist,” Journal of Medicinal Chemistry, vol. 32, no. 6, pp. 1145–1147, 1989.
[22] D. J. Fretland, D. L. Widomski, J. M. Zemaitis, S. W. Djuric, and R. L. Shone, “Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in canine dermis,” Inflammation, vol. 13, no. 5, pp. 601–605, 1989.
[23] B. S. Tsai, R. J. Cooper, and A. H. Hiebert, “SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions,” Prostaglandins, vol. 38, no. 6, pp. 655–674, 1989.
[24] K. Kishikawa, M. S. Simonson, J. A. Wolfe, and M. J. Dunn, “Regulation of differential expression of the gene encoding prostaglandin endoperoxide synthase,” in Advances in Prostaglandin, Thromboxane and Leukotriene Research, B. Sammuelsson, P. Ramwell, and R. Paolotti, Eds., pp. 21–69, Raven Press, New York, NY, USA, 1990.
against leukotriene B4 in humans,” *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*, vol. 23, pp. 279–281, 1995.

[26] D. M. Gapinski, B. E. Mallett, L. L. Froelich, and W. T. Jackson, “Benzoephene dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain,” *Journal of Medicinal Chemistry*, vol. 33, no. 10, pp. 2807–2813, 1990.

[27] W. T. Jackson, R. J. Boyd, L. L. Froelich, B. E. Mallett, and D. M. Gapinski, “Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 263, no. 3, pp. 1099–1104, 1992.

[28] P. Marder, J. S. Sawyer, L. L. Froelich, L. L. Mann, and S. M. Spaethe, “Blockade of human neutrophil activation by 2-[2-propyl-3-[3-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxo]-propoxy]-phenoxy-benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist,” *Biological Pharmacology*, vol. 49, no. 11, pp. 1683–1690, 1995.

[29] J. S. Sawyer, N. J. Bach, S. R. Baker, et al., “Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxo]-propoxy]-phenoxy-benzoic acid, a high-affinity leukotriene B4 receptor antagonist,” *Journal of Medicinal Chemistry*, vol. 38, no. 22, pp. 4411–4432, 1995.

[30] J. S. Sawyer, “LY293111Na,” *Drugs of the Future*, vol. 21, pp. 610–614, 1996.

[31] L. M. Coussens and Z. Werb, “Inflammation and cancer,” *Drugs of the Future*, vol. 9, no. 2, pp. 123–130, 2004.

[32] M. Macarthur, G. L. Hold, and E. M. El-Omar, “Inflammation and pancreatic cancer,” *Molecular Medicine*, vol. 91, no. 4, pp. 737–743, 2001.

[33] W. G. Nelson, A. M. De Marzo, T. L. DeWeese, et al., “The role of inflammation in the pathogenesis of prostate cancer,” *The Journal of Urology*, vol. 172, no. 5, supplement 1, pp. S6–S12, 2004.

[34] C. Bréchot, “Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms,” *Gastroenterology*, vol. 127, no. 5, supplement 1, pp. S56–S61, 2004.

[35] A. Tannapfel, “Molecular findings in Barrett’s epithelium,” *Digestive Diseases*, vol. 22, no. 2, pp. 126–133, 2004.

[36] H. Clevers, “At the crossroads of inflammation and cancer,” *Cell*, vol. 118, no. 6, pp. 671–674, 2004.

[37] C. Stoicov, R. Saffari, X. Cai, C. Hasyagar, and J. Houghton, “Molecular biology of gastric cancer: helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling,” *Gene*, vol. 341, no. 1-2, pp. 1–17, 2004.

[38] A. D. Feld, “Malpractice risks associated with colon cancer and inflammatory bowel disease,” *American Journal of Gastroenterology*, vol. 99, no. 9, pp. 1641–1644, 2004.

[39] S. Zha, V. Vignasubramanian, W. G. Nelson, W. B. Isaacs, and A. M. De Marzo, “Cyclooxygenases in cancer: progress and perspective,” *Cancer Letters*, vol. 215, no. 1, pp. 1–20, 2004.

[40] C. J. van der Wonde, J. H. Kleibeuker, P. L. M. Jansen, and H. Moshage, “Chronic inflammation, apoptosis and (pre)malignant lesions in the gastro-intestinal tract,” *Apoptosis*, vol. 9, no. 2, pp. 123–130, 2004.

[41] B. Farrow and B. M. Evers, “Inflammation and the development of pancreatic cancer,” *Surgical Oncology*, vol. 10, no. 4, pp. 153–169, 2002.

[42] O. C. Trifan and T. Hla, “Cyclooxygenase-2 modulates cellular growth and promotes tumorogenesis,” *Journal of Cellular and Molecular Medicine*, vol. 7, no. 3, pp. 207–222, 2003.

[43] X.-Z. Ding, W.-G. Tong, and T. E. Adrian, “Cyclooxygenases and lipoxigenases as potential targets for treatment of pancreatic cancer,” *Pancreatology*, vol. 1, no. 4, pp. 291–299, 2001.

[44] Y. Cao and S. M. Prescott, “Many actions of cyclooxygenase-2 in cellular dynamics and in cancer,” *Journal of Cellular Physiology*, vol. 190, no. 3, pp. 279–286, 2002.

[45] E. Fosslien, “Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis,” *Annals of Clinical and Laboratory Science*, vol. 31, no. 4, pp. 325–348, 2001.

[46] S. Gately and W. W. Li, “Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy,” *Seminars in Oncology*, vol. 31, supplement 7, pp. 2–11, 2004.

[47] C. Rüegg, O. Dormond, and A. Mariotti, “Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis,” *Biochimica et Biophysica Acta*, vol. 1654, no. 1, pp. 51–67, 2004.

[48] M. J. Thun, “Aspirin, NSAIDs, and digestive tract cancers,” *Cancer and Metastasis Reviews*, vol. 13, no. 3-4, pp. 269–277, 1994.

[49] M. J. Thun, “NSAID use and decreased risk of gastrointestinal cancers,” *Gastroenterology Clinics of North America*, vol. 25, no. 2, pp. 333–348, 1996.

[50] G. N. Levy, “Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer,” *The FASEB Journal*, vol. 11, no. 4, pp. 234–247, 1997.

[51] J. A. Baron and R. S. Sandler, “Nonsteroidal anti-inflammatory drugs and cancer prevention,” *Annual Review of Medicine*, vol. 51, pp. 511–523, 2000.

[52] T. J. Kennedy, C.-Y. Chan, X.-Z. Ding, and T. E. Adrian, “Lipoxygenase inhibitors for the treatment of pancreatic cancer,” *Expert Review of Anticancer Therapy*, vol. 3, no. 4, pp. 525–536, 2003.

[53] C. E. Myers and J. Ghosh, “Lipoxygenase inhibition in prostate cancer,” *European Urology*, vol. 35, no. 5-6, pp. 395–398, 1999.

[54] W. G. Jiang, A. Douglas-Jones, and R. E. Mansel, “Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer,” *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 69, no. 4, pp. 275–281, 2003.

[55] M. Matsuyama, R. Yoshimura, M. Mitsuhashi, et al., “Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors,” *International Journal of Oncology*, vol. 24, no. 4, pp. 821–827, 2004.

[56] S. Gupta, M. Srivastava, N. Ahmad, K. Sakamoto, D. G. Bostwick, and H. Mukhtar, “Lipoxygenase-5 is overexpressed in prostate adenocarcinoma,” *Cancer*, vol. 91, no. 4, pp. 737–743, 2001.

[57] J. Ghosh and C. E. Myers, “Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 22, pp. 13182–13187, 1998.

[58] J. Ghosh and C. E. Myers, “Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells,” *Advances in Experimental Medicine and Biology*, vol. 469, pp. 577–582, 1999.

[59] K. M. Anderson, T. Seed, J. Meng, D. Ou, W. A. Alrefai, and J. E. Harris, “Five-lipoxygenase inhibitors reduce PANc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid,” *Anticancer Research*, vol. 18, no. 2, pp. 791–800, 1998.
[60] M. Romano, A. Catalano, M. Nutini, et al., “5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor,” *The FASEB Journal*, vol. 15, no. 13, pp. 2326–2336, 2001.

[61] X.-Z. Ding, W.-G. Tong, and T. E. Adrian, “Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer,” *Oncology*, vol. 65, no. 4, pp. 285–294, 2003.

[62] W.-G. Tong, X.-Z. Ding, M. S. Talamonti, R. H. Bell, and T. E. Adrian, “LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways,” *Biochemical and Biophysical Research Communications*, vol. 335, no. 3, pp. 949–956, 2005.

[63] X.-Z. Ding, W.-G. Tong, and T. E. Adrian, “12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation,” *International Journal of Cancer*, vol. 94, no. 5, pp. 630–636, 2001.

[64] R. Hennig, T. Kehl, S. Noor, et al., “15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth,” *Neoplasia*, vol. 9, no. 11, pp. 917–926, 2007.

[65] R. Hennig, X.-Z. Ding, W.-G. Tong, et al., “5-lipoxygenase and leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue,” *American Journal of Pathology*, vol. 161, no. 2, pp. 421–428, 2002.

[66] R. Hennig, P. Gripp, X.-Z. Ding, et al., “5-lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions,” *Cancer Research*, vol. 65, no. 14, pp. 6011–6016, 2005.

[67] X.-Z. Ding, C. A. Kuszynski, T. H. El-Metwally, and T. E. Adrian, “Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells,” *Biochemical and Biophysical Research Communications*, vol. 266, no. 2, pp. 392–399, 1999.

[68] X.-Z. Ding, P. Iversen, M. W. Cluck, J. A. Knezetic, and T. E. Adrian, “Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells,” *Biochemical and Biophysical Research Communications*, vol. 261, no. 1, pp. 218–223, 1999.

[69] W. G. Tong, X. Z. Ding, R. C. Witt, and T. E. Adrian, “Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway,” *Molecular Cancer Therapeutics*, vol. 1, no. 11, pp. 929–935, 2002.

[70] R. Hennig, T. Osman, I. Esposito, et al., “BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation,” *British Journal of Cancer*, vol. 99, no. 7, pp. 1064–1073, 2008.

[71] S. J. Roberts-Thomson, “Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment,” *Immunochemistry and Cell Biology*, vol. 78, no. 4, pp. 436–441, 2000.

[72] L. Kopelowich, J. R. Fay, R. I. Glazer, and J. A. Crowell, “Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents,” *Molecular Cancer Therapeutics*, vol. 1, no. 5, pp. 357–363, 2002.

[73] H. P. Koeffler, “Peroxisome proliferator-activated receptor γ and cancers,” *Clinical Cancer Research*, vol. 9, no. 1, pp. 1–9, 2003.

[74] C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” *Lancet Oncology*, vol. 5, no. 7, pp. 419–429, 2004.

[75] W. Motomura, T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo, “Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells,” *Cancer Research*, vol. 60, no. 19, pp. 5558–5564, 2000.

[76] R. G. Mehta, E. Williamson, M. K. Patel, and H. P. Koeffler, “A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions,” *Journal of the National Cancer Institute*, vol. 92, no. 5, pp. 418–423, 2000.

[77] T. Sasaki, Y. Fujimoto, A. Tsuchida, Y. Kawasaki, Y. Kuwada, and K. Chayama, “Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer,” *Pathobiology*, vol. 69, no. 5, pp. 258–265, 2001.

[78] A. Itami, G. Watanabe, Y. Shimada, et al., “Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both in vitro and in vivo,” *International Journal of Cancer*, vol. 94, no. 3, pp. 370–376, 2001.

[79] G. Eibl, M. N. Wente, H. A. Reber, and O. J. Hines, “Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis,” *Biochemical and Biophysical Research Communications*, vol. 287, no. 2, pp. 522–529, 2001.

[80] S. Kawa, T. Nikiad, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone,” *Pancreas*, vol. 24, no. 1, pp. 1–7, 2002.

[81] K. Hashimoto, B. J. Farrow, and B. M. Evers, “Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2,” *Pancreas*, vol. 28, no. 2, pp. 153–159, 2004.

[82] E. Ceni, T. Mello, M. Tarocchi, et al., “Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells,” *World Journal of Gastroenterology*, vol. 11, no. 8, pp. 1122–1130, 2005.

[83] W. Motomura, M. Nagamine, S. Tanno, et al., “Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells,” *Journal of Gastroenterology*, vol. 39, no. 5, pp. 461–468, 2004.

[84] A. Galli, E. Ceni, D. W. Crabb, et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms,” *Gut*, vol. 53, no. 11, pp. 1688–1697, 2004.

[85] G. Eibl, Y. Takata, L. G. Boros, et al., “Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor,” *Cancer Research*, vol. 65, no. 3, pp. 982–990, 2005.

[86] W.-G. Tong, X.-Z. Ding, R. Hennig, et al., “Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells,” *Clinical Cancer Research*, vol. 8, no. 10, pp. 3232–3242, 2002.

[87] W.-G. Tong, X.-Z. Ding, M. S. Talamonti, R. H. Bell, and T. E. Adrian, “Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells,” *Anti-Cancer Drugs*, vol. 18, no. 5, pp. 535–541, 2007.

[88] W.-G. Tong, X.-Z. Ding, and T. E. Adrian, “The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells,” *Biochemical and Biophysical Research Communications*, vol. 296, no. 4, pp. 942–948, 2002.

[89] R. Hennig, X.-Z. Ding, W.-G. Tong, R. C. Witt, B. D. Jovanovic, and T. E. Adrian, “Effect of LY293111 in combination with gemcitabine in colonic cancer,” *Cancer Letters*, vol. 210, no. 1, pp. 41–46, 2004.

[90] R. C. Falcone and D. Aharony, “Modulation of ligand binding to leukotriene B4 receptor on guinea pig lung membranes to sulfhydryl modifying reagents,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 255, no. 2, pp. 565–571, 1990.
[91] R. Hennig, J. Ventura, R. Segersvard, et al., “LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice,” *Neoplasia*, vol. 7, no. 4, pp. 417–425, 2005.

[92] M. S. Marshall, B. Diaz, J. Brozinick, et al., “LY293111 inhibits tumor cell growth cell growth in vitro through an apparent PPARgamma agonist activity,” in *Proceedings 93rd Annual Meeting of American Association for Cancer Research (AACR ’02)*, vol. 43, p. 957, San Francisco, Calif, USA, April 2002.

[93] M. S. Marshall, B. Diaz, J. Copp, et al., “The LTB4 receptor antagonist, LY293111 inhibits tumor cell growth in vitro independent of the LTB4 receptor,” in *Proceedings 93rd Annual Meeting of American Association for Cancer Research (AACR ’02)*, vol. 43, p. 963, San Francisco, Calif, USA, April 2002.

[94] D. R. Budman and A. Calabro, “Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111,” *Anti-Cancer Drugs*, vol. 15, no. 9, pp. 877–881, 2004.

[95] G. K. Schwartz, D. R. Budman, S. Endres, et al., “Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPARγ),” in *Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO ’02)*, vol. 21, Orlando, Fla, USA, May 2002, abstract 343.

[96] J. P. Stevenson, D. P. Petrylak, K. Feit, et al., “Phase I and pharmacological trial of LY293111 in combination with gemcitabine,” in *Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO ’02)*, vol. 21, Orlando, Fla, USA, May 2002, abstract 2140.

[97] T. Baetz, E. Eisenhauer, L. Siu, et al., “A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours,” *Investigational New Drugs*, vol. 25, no. 3, pp. 217–225, 2007.

[98] D. A. Richards, H. Oettle, W. L. Vervenne, et al., “Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas,” *Journal of Clinical Oncology*, vol. 23, no. 16s, p. 4092, 2005.

[99] P. A. Janne, P.-A. Rodriguez, M. Gottfried, et al., “Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosanoid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma,” *Journal of Clinical Oncology*, vol. 24, no. 18s, p. 7024, 2006.